

## Faculty Disclosures

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, course directors, planners, moderators, faculty, and all others in control of the educational content of the continuing education activity must disclose all financial relationships with ineligible companies that they may have had within the past 24 months. If an individual refuses to disclose financial relationships, they will be disqualified from being a part of the planning and implementation of the activity. Owners and/or employees of an ineligible company with business lines or products relating to the content of the activity will not be permitted to participate in the planning or execution of any accredited program. All listed relevant financial relationships with ineligible companies for individuals in control of content have been mitigated.

Name	Role in Activity	Ineligible Company	Nature of Relevant Financial Relationship
<b>Bhangoo</b>	Speaker	<ul style="list-style-type: none"> <li>Bristol Myers Squibb, Exelixis</li> </ul>	<ul style="list-style-type: none"> <li>Speaker</li> </ul>
<b>Bollin</b>	Speaker	<ul style="list-style-type: none"> <li>None</li> </ul>	<ul style="list-style-type: none"> <li>N/A</li> </ul>
<b>Bowman</b>	Speaker	<ul style="list-style-type: none"> <li>Caris Life Sciences, Natera, Inc.</li> <li>Astellas, AstraZeneca, Janssen, Seagen</li> </ul>	<ul style="list-style-type: none"> <li>Speakers Bureau</li> <li>Consultant/Advisory Board</li> </ul>
<b>Dorff</b>	Speaker	<ul style="list-style-type: none"> <li>Astellas, AstraZeneca, Exelixis, Janssen, Pfizer, Seagen</li> </ul>	<ul style="list-style-type: none"> <li>Advisor</li> </ul>
<b>Dragovich</b>	Speaker	<ul style="list-style-type: none"> <li>None</li> </ul>	<ul style="list-style-type: none"> <li>N/A</li> </ul>
<b>Goodman</b>	Speaker	<ul style="list-style-type: none"> <li>Seattle Genetics</li> </ul>	<ul style="list-style-type: none"> <li>Consultant</li> </ul>
<b>Hecht</b>	Speaker	<ul style="list-style-type: none"> <li>Astellas, AstraZeneca, Concept Pharmaceuticals, Exelixis, Gilead, Sciences, Gritstone, Istari Oncology, Regenacy Pharmaceuticals, Notch Therapeutics</li> <li>Amgen</li> </ul>	<ul style="list-style-type: none"> <li>Advisor</li> <li>Speaker</li> </ul>
<b>Lida</b>	Speaker	<ul style="list-style-type: none"> <li>None</li> </ul>	<ul style="list-style-type: none"> <li>N/A</li> </ul>
<b>Madan</b>	Speaker	<ul style="list-style-type: none"> <li>None</li> </ul>	<ul style="list-style-type: none"> <li>N/A</li> </ul>
<b>Mahindra</b>	Speaker	<ul style="list-style-type: none"> <li>ADC Therapeutics, Bristol Myers Squibb, EUSA Pharma, Epizyme, GlaxoSmithKline, Karyopharm Therapeutics</li> <li>GlaxoSmithKline</li> </ul>	<ul style="list-style-type: none"> <li>Advisory</li> <li>Speaker</li> </ul>
<b>Mahmoud</b>	Speaker	<ul style="list-style-type: none"> <li>None</li> </ul>	<ul style="list-style-type: none"> <li>N/A</li> </ul>
<b>Mortimer</b>	Speaker	<ul style="list-style-type: none"> <li>AstraZeneca, Novartis, Pfizer</li> <li>AstraZeneca</li> </ul>	<ul style="list-style-type: none"> <li>Consultant</li> <li>Research Funding</li> </ul>
<b>Natale</b>	Speaker	<ul style="list-style-type: none"> <li>Astex Pharmaceuticals, AstraZeneca, Blueprint Pharmaceuticals, Inspirna Pharmaceuticals, Merck &amp; CO., Molecular Templates</li> </ul>	<ul style="list-style-type: none"> <li>Clinical Research</li> </ul>

<b>Niu</b>	Speaker	<ul style="list-style-type: none"> <li>AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Merck, Mirati, Takeda</li> <li>Onclive, MD Outlook, Research to Practice, Projects in Knowledge, The Arizona Clinical Oncology Society (TACOS), Optum Health Education</li> </ul>	<ul style="list-style-type: none"> <li>Consultant</li> <li>Speaker</li> </ul>
<b>Saven</b>	Course Director, Moderator	<ul style="list-style-type: none"> <li>Celgene, Dova Pharmaceuticals, Inc., Incyte Corporation, Janssen, Pharmacyclics, Seattle Genetics</li> </ul>	<ul style="list-style-type: none"> <li>Speaker</li> </ul>
<b>CME Committee</b>	CE approval, all final decision-making on activities	<ul style="list-style-type: none"> <li>None</li> </ul>	<ul style="list-style-type: none"> <li>N/A</li> </ul>
<b>Scripps Conference Services &amp; CME</b>	Plan, manage, implement, and reconcile CE activities	<ul style="list-style-type: none"> <li>None</li> </ul>	<ul style="list-style-type: none"> <li>N/A</li> </ul>

**Glossary of Terms**

**Ineligible Company**

An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. For specific examples of ineligible companies visit [www.accme.org/standards](http://www.accme.org/standards).

**Financial Relationships**

Financial relationships include employee, researcher, consultant, advisor, speaker, independent contractor, research funding, royalties or patent beneficiary, executive role, and ownership interest. Individual stocks and stock options should be disclosed.